Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tribute Pharmaceuticals developed and marketed a portfolio of specialty pharmaceuticals focused on pain, cardiovascular, dermatology, and allergy indications primarily in Canada. Flagship products included diclofenac potassium for migraines (Cambia), bezafibrate for hyperlipidemia (Bezalip SR), extended-release tramadol for pain (Durela), acitretin for psoriasis (Soriatane), and others. The company was acquired by Pozen and merged into Aralez Pharmaceuticals in 2016; much of its commercial portfolio was maintained post-acquisition.[2][3][10]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Tribute Pharmaceuticals.